Skip to main content

Table 2 Baseline ECM-neoepitope biomarker concentrations stratified by treatment group

From: LPA1 antagonist BMS-986020 changes collagen dynamics and exerts antifibrotic effects in vitro and in patients with idiopathic pulmonary fibrosis

ECM-neoepitope biomarkera

Baseline biomarker concentration, mean (SEM), ng/mL

BMS-986020

600 mg QD

BMS-986020

600 mg BID

Placebo

C1M

36.4 (5.0)

27.3 (2.4)

25.6 (1.7)

C3A

53.3 (2.0)

48.4 (2.7)

43.1 (3.1)

C3M

13.0 (0.6)

11.9 (0.5)

11.5 (0.5)

C4M2*

31.3 (3.6)

24.2 (2.0)

22.4 (1.7)

C6M

25.4 (2.3)

22.5 (1.4)

20.5 (1.2)

PRO-C3

13.7 (1.6)

14.4 (1.2)

13.3 (1.1)

PRO-C4

296.9 (18.3)

282.3 (14.1)

248.5 (10.9)

PRO-C6

10.8 (0.7)

12.6 (0.9)

12.1 (1.0)

VICM

5.4 (0.9)

6.7 (1.6)

5.1 (0.7)

  1. No other neoepitope markers showed significant differences at baseline by treatment arm. ECM-neoepitope biomarker abbreviations are defined in Table 1
  2. BID twice daily; ECM extracellular matrix; QD once daily; SEM standard error of the mean
  3. *Significant difference at baseline between treatment arms identified by Kruskal–Wallis test (P = 0.045)
  4. aPatient numbers for each ECM-neoepitope biomarker and treatment group are listed in Fig. 4
Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us